21:53:46 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2021-03-01 07:30:13
OSLO/LONDON, MARCH 1st 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company today announced that its
proprietary Acoustic Cluster Therapy (ACT®) platform technology for targeted
therapeutic enhancement will be the subject of a presentation at the forthcoming
ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021.

The ESMO Targeted Anticancer Therapies Virtual Congress 2021 is set to offer
participants a glimpse of the future of targeted anticancer therapies and is the
premier international meeting focusing on promising new anticancer targets and
agents, with a particular focus on those in early phase clinical development.

The presentation will take place on March 1st 2021 and will focus on the
background and rationale of ACT®, preclinical study data and the ongoing Phase I
evaluation. The Phase I ACTIVATE study is evaluating the safety, tolerability,
pharmacokinetics and pharmacodynamics of ACT® when co-administered with standard
of care chemotherapy in patients with metastatic colorectal cancer.


Title: Acoustic cluster therapy (ACT) as a mechanism of increasing drug
delivery: Phase I experience (ID50)

Presenting Author: Prof Udai Banerji, NIHR Professor of Molecular Cancer
Pharmacology and Honorary Consultant in Medical Oncology, Royal Marsden
Hospital, London.

Session: (Educational) Nothing is undruggable! (ID19)

Date/Time: Monday 1st March 2021/ 13.00-13.15

The Targeted Anticancer Therapies 2021 Virtual Congress 2021 will bring together
experts in anticancer drug discovery and clinical development, translational
scientists, and regulators in a unique forum to highlight recent advances and
new data, whilst promoting collaboration and knowledge-sharing in a
bench-to-bedside approach. The TAT meeting is a meeting focused on early
clinical trials and has been described as 'The home of phase I in oncology'.
This meeting will be entirely dedicated to improving the conduct of early
anti-cancer clinical trials, with presentations, discussions and educational
reviews and workshops highlighting emerging pre-clinical and clinical data, as
well as defining optimal methodologies for early clinical trials.

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.


About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

For more information contact:
Dr Rafiq Hasan,
CEO EXACT Therapeutics
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu